Vivasure Medical
- Industry
- Medical Device Manufacturing
- Founded Year
- 2009
- Headquarters
- Parkmore Business Park West, Galway, Ireland, H91 V3KP
- Employee Count
- 54
Key People
- Andrew Glass - Chief Executive Officer
- Gerard Brett - Co-Founder and Chief Operating Officer
- Chris Martin - Co-Founder and Chief Technical Officer
- David Keating - Chief Financial Officer
- Paul Geudens - Chief Commercial Officer
- Brendan Cunniffe - VP Operations and Engineering
- Kevin Timmins - VP Regulatory and Quality Affairs
- Mark McGoldrick - Director Research and Development
- David O'Flynn - VP Business Development
- Paul Teirstein - Chief Medical Officer
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in medical device development and commercialization.
The presence of multiple successful MedTech entrepreneurs in the leadership team provides a strong foundation for strategic decision-making and innovation.
- Clinical Need
-
Aspect: Very Strong
Summary: Vivasure's PerQseal addresses a significant need for fully absorbable, large-bore vessel closure devices in minimally invasive procedures.
The increasing adoption of minimally invasive procedures underscores the demand for effective vessel closure solutions, which PerQseal aims to fulfill.
- Competition
-
Aspect: Somewhat crowded
Summary: The vascular closure device market includes several established players, though Vivasure's fully absorbable technology offers differentiation.
The presence of competitors necessitates strategic positioning, but Vivasure's innovative approach may capture market share.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing fully absorbable vascular closure devices involves moderate technical challenges, which Vivasure has addressed through its proprietary technology.
The development of bioabsorbable materials and delivery systems requires specialized expertise, which Vivasure possesses.
- Patent
-
Aspect: Strong
Summary: Vivasure has developed and patented a platform technology with applications in vessel closure.
A robust patent portfolio protects the company's innovations and provides a barrier to entry for competitors.
- Financing
-
Aspect: Well-funded
Summary: Vivasure has secured significant funding, including a 30M investment from Haemonetics as part of its Series D financing.
Adequate financing enables the company to advance product development, conduct clinical trials, and pursue regulatory approvals.
- Regulatory
-
Aspect: Pivotal Trial
Summary: Vivasure is conducting pivotal trials for its PerQseal device to support regulatory approvals.
Successful completion of pivotal trials is critical for obtaining regulatory approvals and subsequent market entry.
Opportunity Rollup
- Odds of Success
- 4.05
- Peak Market Share
- 5.7
- Segment CAGR
- 5.1%
- Market Segment
- Cardiovascular Devices
- Market Sub Segment
- Vascular Closure Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.29 |
| 2 | 0.86 |
| 3 | 2.00 |
| 4 | 3.99 |
| 5 | 5.70 |
Key Takeaway
Vivasure Medical's innovative, fully absorbable vascular closure devices address a significant clinical need in minimally invasive procedures, supported by a strong team and substantial funding, positioning the company for success in a growing market.